关注
Bradley D. Shields, MD, PhD
Bradley D. Shields, MD, PhD
UPMC
在 uams.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Indicators of responsiveness to immune checkpoint inhibitors
BD Shields, F Mahmoud, EM Taylor, SD Byrum, D Sengupta, B Koss, ...
Scientific reports 7 (1), 807, 2017
922017
Loss of E-cadherin inhibits CD103 antitumor activity and reduces checkpoint blockade responsiveness in melanoma
BD Shields, B Koss, EM Taylor, AJ Storey, KL West, SD Byrum, ...
Cancer research 79 (6), 1113-1123, 2019
582019
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
F Mahmoud, B Shields, I Makhoul, N Avaritt, HK Wong, LF Hutchins, ...
Cancer biology & therapy 18 (7), 451-469, 2017
572017
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
F Mahmoud, B Shields, I Makhoul, LF Hutchins, SC Shalin, AJ Tackett
Cancer biology & therapy 17 (6), 579-591, 2016
532016
Quantitative histone mass spectrometry identifies elevated histone H3 lysine 27 (Lys27) trimethylation in melanoma
D Sengupta, SD Byrum, NL Avaritt, L Davis, B Shields, F Mahmoud, ...
Molecular & Cellular Proteomics 15 (3), 765-775, 2016
332016
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
B Koss, BD Shields, EM Taylor, AJ Storey, SD Byrum, AJ Gies, ...
Cancer research 80 (21), 4707-4719, 2020
252020
Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia
LD Castel, KA Wallston, BR Saville, JAR Alvarez, BD Shields, ID Feurer, ...
Patient Related Outcome Measures, 205-214, 2015
122015
Do checkpoint inhibitors rely on gut microbiota to fight cancer?
B Firwana, N Avaritt, B Shields, R Ravilla, I Makhoul, L Hutchins, ...
Journal of Oncology Pharmacy Practice 24 (6), 468-472, 2018
42018
E-cadherin enhances immune control of metastatic melanoma
BD Shields, B Koss, F Mahmoud, SD Byrum, AJ Tackett
Cancer Research 78 (13_Supplement), 2037-2037, 2018
32018
Proteomics and melanoma: a current perspective
BD Shields, AJ Tackett, SC Shalin
Global dermatology 3 (4), 366, 2016
32016
Microscopes and Mass Spectrometers
B Shields, SC Shalin, AJ Tackett
Journal of proteomics & bioinformatics 9 (Suppl 10), 2016
12016
Methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer
B Shields, A Tackett, S Byrum, F Mahmoud, S Shalin
US Patent 11,561,224, 2023
2023
Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion
B Koss, BD Shields, EM Taylor, AJ Storey, SD Byrum, AJ Gies, ...
Cancer Research 80 (16_Supplement), 1029-1029, 2020
2020
Abstract LB-182: Combination of sulforaphane and 5-aza-2′-deoxycytidine slows the growth and upregulates the chemoattractant CCL5 in metastatic melanoma
TC Chiang, B Koss, AJ Storey, J Zabaleta, SR Choudhury, BD Shields, ...
Cancer Research 80 (16_Supplement), LB-182-LB-182, 2020
2020
Combination of sulforaphane and 5-aza-2'-deoxycytidine slows the growth and upregulates the chemoattractant CCL5 in metastatic melanoma
TC Chiang, B Koss, AJ Storey, J Zabaleta, SR Choudhury, BD Shields, ...
CANCER RESEARCH 80 (16), 2020
2020
Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
BD Shields, F Mahmoud, EM Taylor, SD Byrum, D Sengupta, B Koss, ...
Cancer Research 77 (13_Supplement), LB-206-LB-206, 2017
2017
Epigenetic Control of Cdkn2a. Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic
B Koss, BD Shields, EM Taylor, AJ Storey, SD Byrum, AJ Gies, ...
系统目前无法执行此操作,请稍后再试。
文章 1–17